APO Research
Talk to an analyst

APO RESEARCH · REPORT

Uric Acid Production Inhibitors

Compare research editions
View pricing & licenses

Selected research

Industry Research

Uric Acid Production Inhibitors Industry Research Report 2026

27 December 2025121 pages

Choose your research edition.

Industry ResearchUric Acid Production Inhibitors Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Uric Acid Production Inhibitors Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Uric Acid Production Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Uric Acid Production Inhibitors Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Uric Acid Production Inhibitors Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Uric Acid Production Inhibitors market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Uric Acid Production Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Uric Acid Production Inhibitors is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Uric Acid Production Inhibitors is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Uric Acid Production Inhibitors include Wanbang Biopharmaceuticals, Sanwa Kagaku Kenkyusho, Qingdao Baheal Medical, Jiangsu Hengrui Pharmaceuticals, CR Double-Crane Pharmaceuticals, GKH Pharmaceutical, Zydus, Teva and Takeda, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Uric Acid Production Inhibitors market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Uric Acid Production Inhibitors Market by Company

Wanbang Biopharmaceuticals

Sanwa Kagaku Kenkyusho

Qingdao Baheal Medical

Jiangsu Hengrui Pharmaceuticals

CR Double-Crane Pharmaceuticals

GKH Pharmaceutical

Zydus

Teva

Takeda

Sun Pharmaceutical

GSK

Cipla

Avet Pharmaceuticals

Aurobindo Pharma

Uric Acid Production Inhibitors Segment by Type

Topiroxostat

Febuxostat

Allopurinol

Other

Uric Acid Production Inhibitors Segment by Application

Cancer

Kidney Stones

Gout

Other

Uric Acid Production Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Uric Acid Production Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Uric Acid Production Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Uric Acid Production Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Uric Acid Production Inhibitors manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Uric Acid Production Inhibitors by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Uric Acid Production Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Uric Acid Production Inhibitors Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Uric Acid Production Inhibitors Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Uric Acid Production Inhibitors Sales Market Share by Manufacturers (2021-2026) Table 8. Global Uric Acid Production Inhibitors Revenue of Manufacturers (2021-2026) Table 9. Global Uric Acid Production Inhibitors Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Uric Acid Production Inhibitors Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Uric Acid Production Inhibitors Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Uric Acid Production Inhibitors, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Uric Acid Production Inhibitors, Product Type & Application Table 14. Global Uric Acid Production Inhibitors Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Uric Acid Production Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Wanbang Biopharmaceuticals Company Information Table 19. Wanbang Biopharmaceuticals Business Overview Table 20. Wanbang Biopharmaceuticals Uric Acid Production Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Wanbang Biopharmaceuticals Uric Acid Production Inhibitors Product Portfolio Table 22. Wanbang Biopharmaceuticals Recent Developments Table 23. Sanwa Kagaku Kenkyusho Company Information Table 24. Sanwa Kagaku Kenkyusho Business Overview Table 25. Sanwa Kagaku Kenkyusho Uric Acid Production Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Sanwa Kagaku Kenkyusho Uric Acid Production Inhibitors Product Portfolio Table 27. Sanwa Kagaku Kenkyusho Recent Developments Table 28. Qingdao Baheal Medical Company Information Table 29. Qingdao Baheal Medical Business Overview Table 30. Qingdao Baheal Medical Uric Acid Production Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Qingdao Baheal Medical Uric Acid Production Inhibitors Product Portfolio Table 32. Qingdao Baheal Medical Recent Developments Table 33. Jiangsu Hengrui Pharmaceuticals Company Information Table 34. Jiangsu Hengrui Pharmaceuticals Business Overview Table 35. Jiangsu Hengrui Pharmaceuticals Uric Acid Production Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Jiangsu Hengrui Pharmaceuticals Uric Acid Production Inhibitors Product Portfolio Table 37. Jiangsu Hengrui Pharmaceuticals Recent Developments Table 38. CR Double-Crane Pharmaceuticals Company Information Table 39. CR Double-Crane Pharmaceuticals Business Overview Table 40. CR Double-Crane Pharmaceuticals Uric Acid Production Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. CR Double-Crane Pharmaceuticals Uric Acid Production Inhibitors Product Portfolio Table 42. CR Double-Crane Pharmaceuticals Recent Developments Table 43. GKH Pharmaceutical Company Information Table 44. GKH Pharmaceutical Business Overview Table 45. GKH Pharmaceutical Uric Acid Production Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. GKH Pharmaceutical Uric Acid Production Inhibitors Product Portfolio Table 47. GKH Pharmaceutical Recent Developments Table 48. Zydus Company Information Table 49. Zydus Business Overview Table 50. Zydus Uric Acid Production Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Zydus Uric Acid Production Inhibitors Product Portfolio Table 52. Zydus Recent Developments Table 53. Teva Company Information Table 54. Teva Business Overview Table 55. Teva Uric Acid Production Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Teva Uric Acid Production Inhibitors Product Portfolio Table 57. Teva Recent Developments Table 58. Takeda Company Information Table 59. Takeda Business Overview Table 60. Takeda Uric Acid Production Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Takeda Uric Acid Production Inhibitors Product Portfolio Table 62. Takeda Recent Developments Table 63. Sun Pharmaceutical Company Information Table 64. Sun Pharmaceutical Business Overview Table 65. Sun Pharmaceutical Uric Acid Production Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Sun Pharmaceutical Uric Acid Production Inhibitors Product Portfolio Table 67. Sun Pharmaceutical Recent Developments Table 68. GSK Company Information Table 69. GSK Business Overview Table 70. GSK Uric Acid Production Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. GSK Uric Acid Production Inhibitors Product Portfolio Table 72. GSK Recent Developments Table 73. Cipla Company Information Table 74. Cipla Business Overview Table 75. Cipla Uric Acid Production Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Cipla Uric Acid Production Inhibitors Product Portfolio Table 77. Cipla Recent Developments Table 78. Avet Pharmaceuticals Company Information Table 79. Avet Pharmaceuticals Business Overview Table 80. Avet Pharmaceuticals Uric Acid Production Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Avet Pharmaceuticals Uric Acid Production Inhibitors Product Portfolio Table 82. Avet Pharmaceuticals Recent Developments Table 83. Aurobindo Pharma Company Information Table 84. Aurobindo Pharma Business Overview Table 85. Aurobindo Pharma Uric Acid Production Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Aurobindo Pharma Uric Acid Production Inhibitors Product Portfolio Table 87. Aurobindo Pharma Recent Developments Table 88. Global Uric Acid Production Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 89. Global Uric Acid Production Inhibitors Sales by Region (2021-2026) & (K Units) Table 90. Global Uric Acid Production Inhibitors Sales Market Share by Region (2021-2026) Table 91. Global Uric Acid Production Inhibitors Sales by Region (2027-2032) & (K Units) Table 92. Global Uric Acid Production Inhibitors Sales Market Share by Region (2027-2032) Table 93. Global Uric Acid Production Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 94. Global Uric Acid Production Inhibitors Revenue Market Share by Region (2021-2026) Table 95. Global Uric Acid Production Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 96. Global Uric Acid Production Inhibitors Revenue Market Share by Region (2027-2032) Table 97. North America Uric Acid Production Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. North America Uric Acid Production Inhibitors Sales by Country (2021-2026) & (K Units) Table 99. North America Uric Acid Production Inhibitors Sales by Country (2027-2032) & (K Units) Table 100. North America Uric Acid Production Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 101. North America Uric Acid Production Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 102. Europe Uric Acid Production Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Europe Uric Acid Production Inhibitors Sales by Country (2021-2026) & (K Units) Table 104. Europe Uric Acid Production Inhibitors Sales by Country (2027-2032) & (K Units) Table 105. Europe Uric Acid Production Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 106. Europe Uric Acid Production Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 107. Asia Pacific Uric Acid Production Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Asia Pacific Uric Acid Production Inhibitors Sales by Country (2021-2026) & (K Units) Table 109. Asia Pacific Uric Acid Production Inhibitors Sales by Country (2027-2032) & (K Units) Table 110. Asia Pacific Uric Acid Production Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 111. Asia Pacific Uric Acid Production Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 112. South America Uric Acid Production Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. South America Uric Acid Production Inhibitors Sales by Country (2021-2026) & (K Units) Table 114. South America Uric Acid Production Inhibitors Sales by Country (2027-2032) & (K Units) Table 115. South America Uric Acid Production Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 116. South America Uric Acid Production Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 117. Middle East and Africa Uric Acid Production Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Middle East and Africa Uric Acid Production Inhibitors Sales by Country (2021-2026) & (K Units) Table 119. Middle East and Africa Uric Acid Production Inhibitors Sales by Country (2027-2032) & (K Units) Table 120. Middle East and Africa Uric Acid Production Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 121. Middle East and Africa Uric Acid Production Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 122. Global Uric Acid Production Inhibitors Sales by Type (2021-2026) & (K Units) Table 123. Global Uric Acid Production Inhibitors Sales by Type (2027-2032) & (K Units) Table 124. Global Uric Acid Production Inhibitors Sales Market Share by Type (2021-2026) Table 125. Global Uric Acid Production Inhibitors Sales Market Share by Type (2027-2032) Table 126. Global Uric Acid Production Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 127. Global Uric Acid Production Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 128. Global Uric Acid Production Inhibitors Revenue Market Share by Type (2021-2026) Table 129. Global Uric Acid Production Inhibitors Revenue Market Share by Type (2027-2032) Table 130. Global Uric Acid Production Inhibitors Price by Type (2021-2026) & (US$/Unit) Table 131. Global Uric Acid Production Inhibitors Price by Type (2027-2032) & (US$/Unit) Table 132. Global Uric Acid Production Inhibitors Sales by Application (2021-2026) & (K Units) Table 133. Global Uric Acid Production Inhibitors Sales by Application (2027-2032) & (K Units) Table 134. Global Uric Acid Production Inhibitors Sales Market Share by Application (2021-2026) Table 135. Global Uric Acid Production Inhibitors Sales Market Share by Application (2027-2032) Table 136. Global Uric Acid Production Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 137. Global Uric Acid Production Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 138. Global Uric Acid Production Inhibitors Revenue Market Share by Application (2021-2026) Table 139. Global Uric Acid Production Inhibitors Revenue Market Share by Application (2027-2032) Table 140. Global Uric Acid Production Inhibitors Price by Application (2021-2026) & (US$/Unit) Table 141. Global Uric Acid Production Inhibitors Price by Application (2027-2032) & (US$/Unit) Table 142. Key Raw Materials Table 143. Raw Materials Key Suppliers Table 144. Uric Acid Production Inhibitors Distributors List Table 145. Uric Acid Production Inhibitors Customers List Table 146. Uric Acid Production Inhibitors Industry Trends Table 147. Uric Acid Production Inhibitors Industry Drivers Table 148. Uric Acid Production Inhibitors Industry Restraints Table 149. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Uric Acid Production Inhibitors Product Image Figure 5. Global Uric Acid Production Inhibitors Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Uric Acid Production Inhibitors Market Size (2021-2032) & (US$ Million) Figure 7. Global Uric Acid Production Inhibitors Sales (2021-2032) & (K Units) Figure 8. Global Uric Acid Production Inhibitors Average Price (US$/Unit) & (2021-2032) Figure 9. Topiroxostat Product Image Figure 10. Febuxostat Product Image Figure 11. Allopurinol Product Image Figure 12. Other Product Image Figure 13. Cancer Product Image Figure 14. Kidney Stones Product Image Figure 15. Gout Product Image Figure 16. Other Product Image Figure 17. Global Uric Acid Production Inhibitors Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Uric Acid Production Inhibitors, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Uric Acid Production Inhibitors Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Uric Acid Production Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Uric Acid Production Inhibitors Sales by Region in 2025 Figure 23. Global Uric Acid Production Inhibitors Revenue by Region in 2025 Figure 24. North America Uric Acid Production Inhibitors Market Size by Country in 2025 Figure 25. North America Uric Acid Production Inhibitors Sales Market Share by Country (2021-2032) Figure 26. North America Uric Acid Production Inhibitors Revenue Market Share by Country (2021-2032) Figure 27. United States Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Mexico Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Uric Acid Production Inhibitors Market Size by Country in 2025 Figure 31. Europe Uric Acid Production Inhibitors Sales Market Share by Country (2021-2032) Figure 32. Europe Uric Acid Production Inhibitors Revenue Market Share by Country (2021-2032) Figure 33. Germany Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Russia Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Spain Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Netherlands Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Switzerland Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Sweden Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Poland Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Asia Pacific Uric Acid Production Inhibitors Market Size by Country in 2025 Figure 44. Asia Pacific Uric Acid Production Inhibitors Sales Market Share by Country (2021-2032) Figure 45. Asia Pacific Uric Acid Production Inhibitors Revenue Market Share by Country (2021-2032) Figure 46. China Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Japan Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South Korea Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. India Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Australia Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Taiwan Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. South America Uric Acid Production Inhibitors Market Size by Country in 2025 Figure 55. South America Uric Acid Production Inhibitors Sales Market Share by Country (2021-2032) Figure 56. South America Uric Acid Production Inhibitors Revenue Market Share by Country (2021-2032) Figure 57. Brazil Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Argentina Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Chile Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Middle East and Africa Uric Acid Production Inhibitors Market Size by Country in 2025 Figure 61. Middle East and Africa Uric Acid Production Inhibitors Sales Market Share by Country (2021-2032) Figure 62. Middle East and Africa Uric Acid Production Inhibitors Revenue Market Share by Country (2021-2032) Figure 63. Egypt Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. South Africa Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Israel Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Türkiye Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. GCC Countries Uric Acid Production Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Global Uric Acid Production Inhibitors Sales Market Share by Type (2021-2032) Figure 69. Global Uric Acid Production Inhibitors Revenue Market Share by Type (2021-2032) Figure 70. Global Uric Acid Production Inhibitors Price (US$/Unit) by Type (2021-2032) Figure 71. Global Uric Acid Production Inhibitors Sales Market Share by Application (2021-2032) Figure 72. Global Uric Acid Production Inhibitors Revenue Market Share by Application (2021-2032) Figure 73. Global Uric Acid Production Inhibitors Price (US$/Unit) by Application (2021-2032) Figure 74. Uric Acid Production Inhibitors Value Chain Figure 75. Uric Acid Production Inhibitors Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Uric Acid Production Inhibitors Industry Opportunities and Challenges

Scope & coverage.

Types
  • Topiroxostat
  • Febuxostat
  • Allopurinol
  • Other
Applications
  • Cancer
  • Kidney Stones
  • Gout
  • Other
Companies covered
  • Wanbang Biopharmaceuticals
  • Sanwa Kagaku Kenkyusho
  • Qingdao Baheal Medical
  • Jiangsu Hengrui Pharmaceuticals
  • CR Double-Crane Pharmaceuticals
  • GKH Pharmaceutical
  • Zydus
  • Teva
  • Takeda
  • Sun Pharmaceutical
  • GSK
  • Cipla
  • Avet Pharmaceuticals
  • Aurobindo Pharma

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Uric Acid Production Inhibitors Market Size (2021-2032)
  4. 2.2.2 Global Uric Acid Production Inhibitors Sales (2021-2032)
  5. 2.2.3 Global Uric Acid Production Inhibitors Market Average Price (2021-2032)
  6. 2.3 Uric Acid Production Inhibitors by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Topiroxostat
  9. 2.3.3 Febuxostat
  10. 2.3.4 Allopurinol
  11. 2.3.5 Other
  12. 2.4 Uric Acid Production Inhibitors by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Cancer
  15. 2.4.3 Kidney Stones
  16. 2.4.4 Gout
  17. 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Uric Acid Production Inhibitors Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Uric Acid Production Inhibitors Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Uric Acid Production Inhibitors Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Uric Acid Production Inhibitors Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Uric Acid Production Inhibitors Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Uric Acid Production Inhibitors, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Uric Acid Production Inhibitors, Product Type & Application
  8. 3.8 Global Manufacturers of Uric Acid Production Inhibitors, Established Date
  9. 3.9 Global Uric Acid Production Inhibitors Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Wanbang Biopharmaceuticals
  2. 4.1.1 Wanbang Biopharmaceuticals Company Information
  3. 4.1.2 Wanbang Biopharmaceuticals Business Overview
  4. 4.1.3 Wanbang Biopharmaceuticals Uric Acid Production Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Wanbang Biopharmaceuticals Uric Acid Production Inhibitors Product Portfolio
  6. 4.1.5 Wanbang Biopharmaceuticals Recent Developments
  7. 4.2 Sanwa Kagaku Kenkyusho
  8. 4.2.1 Sanwa Kagaku Kenkyusho Company Information
  9. 4.2.2 Sanwa Kagaku Kenkyusho Business Overview
  10. 4.2.3 Sanwa Kagaku Kenkyusho Uric Acid Production Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Sanwa Kagaku Kenkyusho Uric Acid Production Inhibitors Product Portfolio
  12. 4.2.5 Sanwa Kagaku Kenkyusho Recent Developments
  13. 4.3 Qingdao Baheal Medical
  14. 4.3.1 Qingdao Baheal Medical Company Information
  15. 4.3.2 Qingdao Baheal Medical Business Overview
  16. 4.3.3 Qingdao Baheal Medical Uric Acid Production Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Qingdao Baheal Medical Uric Acid Production Inhibitors Product Portfolio
  18. 4.3.5 Qingdao Baheal Medical Recent Developments
  19. 4.4 Jiangsu Hengrui Pharmaceuticals
  20. 4.4.1 Jiangsu Hengrui Pharmaceuticals Company Information
  21. 4.4.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  22. 4.4.3 Jiangsu Hengrui Pharmaceuticals Uric Acid Production Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Jiangsu Hengrui Pharmaceuticals Uric Acid Production Inhibitors Product Portfolio
  24. 4.4.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  25. 4.5 CR Double-Crane Pharmaceuticals
  26. 4.5.1 CR Double-Crane Pharmaceuticals Company Information
  27. 4.5.2 CR Double-Crane Pharmaceuticals Business Overview
  28. 4.5.3 CR Double-Crane Pharmaceuticals Uric Acid Production Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 CR Double-Crane Pharmaceuticals Uric Acid Production Inhibitors Product Portfolio
  30. 4.5.5 CR Double-Crane Pharmaceuticals Recent Developments
  31. 4.6 GKH Pharmaceutical
  32. 4.6.1 GKH Pharmaceutical Company Information
  33. 4.6.2 GKH Pharmaceutical Business Overview
  34. 4.6.3 GKH Pharmaceutical Uric Acid Production Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 GKH Pharmaceutical Uric Acid Production Inhibitors Product Portfolio
  36. 4.6.5 GKH Pharmaceutical Recent Developments
  37. 4.7 Zydus
  38. 4.7.1 Zydus Company Information
  39. 4.7.2 Zydus Business Overview
  40. 4.7.3 Zydus Uric Acid Production Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Zydus Uric Acid Production Inhibitors Product Portfolio
  42. 4.7.5 Zydus Recent Developments
  43. 4.8 Teva
  44. 4.8.1 Teva Company Information
  45. 4.8.2 Teva Business Overview
  46. 4.8.3 Teva Uric Acid Production Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Teva Uric Acid Production Inhibitors Product Portfolio
  48. 4.8.5 Teva Recent Developments
  49. 4.9 Takeda
  50. 4.9.1 Takeda Company Information
  51. 4.9.2 Takeda Business Overview
  52. 4.9.3 Takeda Uric Acid Production Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Takeda Uric Acid Production Inhibitors Product Portfolio
  54. 4.9.5 Takeda Recent Developments
  55. 4.10 Sun Pharmaceutical
  56. 4.10.1 Sun Pharmaceutical Company Information
  57. 4.10.2 Sun Pharmaceutical Business Overview
  58. 4.10.3 Sun Pharmaceutical Uric Acid Production Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Sun Pharmaceutical Uric Acid Production Inhibitors Product Portfolio
  60. 4.10.5 Sun Pharmaceutical Recent Developments
  61. 4.11 GSK
  62. 4.11.1 GSK Company Information
  63. 4.11.2 GSK Business Overview
  64. 4.11.3 GSK Uric Acid Production Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 GSK Uric Acid Production Inhibitors Product Portfolio
  66. 4.11.5 GSK Recent Developments
  67. 4.12 Cipla
  68. 4.12.1 Cipla Company Information
  69. 4.12.2 Cipla Business Overview
  70. 4.12.3 Cipla Uric Acid Production Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Cipla Uric Acid Production Inhibitors Product Portfolio
  72. 4.12.5 Cipla Recent Developments
  73. 4.13 Avet Pharmaceuticals
  74. 4.13.1 Avet Pharmaceuticals Company Information
  75. 4.13.2 Avet Pharmaceuticals Business Overview
  76. 4.13.3 Avet Pharmaceuticals Uric Acid Production Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Avet Pharmaceuticals Uric Acid Production Inhibitors Product Portfolio
  78. 4.13.5 Avet Pharmaceuticals Recent Developments
  79. 4.14 Aurobindo Pharma
  80. 4.14.1 Aurobindo Pharma Company Information
  81. 4.14.2 Aurobindo Pharma Business Overview
  82. 4.14.3 Aurobindo Pharma Uric Acid Production Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Aurobindo Pharma Uric Acid Production Inhibitors Product Portfolio
  84. 4.14.5 Aurobindo Pharma Recent Developments
5 Global Uric Acid Production Inhibitors Market Scenario by Region
  1. 5.1 Global Uric Acid Production Inhibitors Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Uric Acid Production Inhibitors Sales by Region: 2021-2032
  3. 5.2.1 Global Uric Acid Production Inhibitors Sales by Region: 2021-2026
  4. 5.2.2 Global Uric Acid Production Inhibitors Sales by Region: 2027-2032
  5. 5.3 Global Uric Acid Production Inhibitors Revenue by Region: 2021-2032
  6. 5.3.1 Global Uric Acid Production Inhibitors Revenue by Region: 2021-2026
  7. 5.3.2 Global Uric Acid Production Inhibitors Revenue by Region: 2027-2032
  8. 5.4 North America Uric Acid Production Inhibitors Market Facts & Figures by Country
  9. 5.4.1 North America Uric Acid Production Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Uric Acid Production Inhibitors Sales by Country (2021-2032)
  11. 5.4.3 North America Uric Acid Production Inhibitors Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Uric Acid Production Inhibitors Market Facts & Figures by Country
  16. 5.5.1 Europe Uric Acid Production Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Uric Acid Production Inhibitors Sales by Country (2021-2032)
  18. 5.5.3 Europe Uric Acid Production Inhibitors Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Uric Acid Production Inhibitors Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Uric Acid Production Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Uric Acid Production Inhibitors Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Uric Acid Production Inhibitors Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Uric Acid Production Inhibitors Market Facts & Figures by Country
  41. 5.7.1 South America Uric Acid Production Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Uric Acid Production Inhibitors Sales by Country (2021-2032)
  43. 5.7.3 South America Uric Acid Production Inhibitors Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Uric Acid Production Inhibitors Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Uric Acid Production Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Uric Acid Production Inhibitors Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Uric Acid Production Inhibitors Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Uric Acid Production Inhibitors Sales by Type (2021-2032)
  2. 6.1.1 Global Uric Acid Production Inhibitors Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Uric Acid Production Inhibitors Sales Market Share by Type (2021-2032)
  4. 6.2 Global Uric Acid Production Inhibitors Revenue by Type (2021-2032)
  5. 6.2.1 Global Uric Acid Production Inhibitors Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Uric Acid Production Inhibitors Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Uric Acid Production Inhibitors Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Uric Acid Production Inhibitors Sales by Application (2021-2032)
  2. 7.1.1 Global Uric Acid Production Inhibitors Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Uric Acid Production Inhibitors Sales Market Share by Application (2021-2032)
  4. 7.2 Global Uric Acid Production Inhibitors Revenue by Application (2021-2032)
  5. 7.2.1 Global Uric Acid Production Inhibitors Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Uric Acid Production Inhibitors Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Uric Acid Production Inhibitors Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Uric Acid Production Inhibitors Value Chain Analysis
  2. 8.1.1 Uric Acid Production Inhibitors Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Uric Acid Production Inhibitors Production Mode & Process
  5. 8.2 Uric Acid Production Inhibitors Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Uric Acid Production Inhibitors Distributors
  8. 8.2.3 Uric Acid Production Inhibitors Customers
9 Global Uric Acid Production Inhibitors Analyzing Market Dynamics
  1. 9.1 Uric Acid Production Inhibitors Industry Trends
  2. 9.2 Uric Acid Production Inhibitors Industry Drivers
  3. 9.3 Uric Acid Production Inhibitors Industry Opportunities and Challenges
  4. 9.4 Uric Acid Production Inhibitors Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst